| Item Type | Name |
|
Concept
|
Research Personnel
|
|
Concept
|
Research Support as Topic
|
|
Concept
|
Research
|
|
Concept
|
Ethics, Research
|
|
Concept
|
Empirical Research
|
|
Concept
|
Research Design
|
|
Concept
|
Biomedical Research
|
|
Concept
|
Comparative Effectiveness Research
|
|
Concept
|
Ethics Committees, Research
|
|
Concept
|
Research Subjects
|
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
|
Academic Article
|
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
|
|
Academic Article
|
Learning from our patients: one participant's impact on clinical trial research and informed consent.
|
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
|
Academic Article
|
Development of target-based antineoplastic agents.
|
|
Academic Article
|
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.
|
|
Academic Article
|
Conflict-of-interest policies.
|
|
Academic Article
|
Clinical trial designs for cytostatic agents.
|
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
|
Academic Article
|
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
|
|
Academic Article
|
Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
|
|
Academic Article
|
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
|
|
Academic Article
|
The pharmacogenetics research network: from SNP discovery to clinical drug response.
|
|
Academic Article
|
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
|
|
Academic Article
|
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
|
|
Academic Article
|
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
|
|
Academic Article
|
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
|
|
Academic Article
|
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
|
|
Academic Article
|
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
|
|
Academic Article
|
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
|
|
Academic Article
|
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
|
|
Academic Article
|
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
|
|
Academic Article
|
The investigational drug steering committee.
|
|
Academic Article
|
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
|
|
Academic Article
|
Nonprofit biomedical companies.
|
|
Academic Article
|
Optimising the design of phase II oncology trials: the importance of randomisation.
|
|
Academic Article
|
Resampling phase III data to assess phase II trial designs and endpoints.
|
|
Academic Article
|
Randomized phase II trials: a long-term investment with promising returns.
|
|
Academic Article
|
Value-based insurance design: aligning incentives, benefits, and evidence in oncology.
|
|
Academic Article
|
Pushing the envelope: informed consent in phase I trials.
|
|
Academic Article
|
Pharmacogenomics and patient care: one size does not fit all.
|
|
Academic Article
|
Dose-escalation models for combination phase I trials in oncology.
|
|
Academic Article
|
Perceptions of cancer patients and their physicians involved in phase I trials.
|
|
Academic Article
|
Measuring response in a post-RECIST world: from black and white to shades of grey.
|
|
Academic Article
|
Opportunities and challenges in the development of experimental drug combinations for cancer.
|
|
Academic Article
|
Cancer pharmacogenomics: strategies and challenges.
|
|
Academic Article
|
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
|
Academic Article
|
Targeted therapies: redefining the primary objective of phase I oncology trials.
|
|
Academic Article
|
Incorporating biomarkers into drug labeling.
|
|
Academic Article
|
Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.
|
|
Academic Article
|
The impact of industry on oncology research and practice.
|
|
Academic Article
|
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
|
Academic Article
|
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
|
|
Academic Article
|
Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.
|
|
Academic Article
|
Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.
|
|
Academic Article
|
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
|
|
Academic Article
|
Burdensome Research Procedures in Trials: Why Less Is More.
|
|
Academic Article
|
Essential Characteristics of Pharmacogenomics Study Publications.
|
|
Academic Article
|
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
|
|
Academic Article
|
Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement.
|
|
Academic Article
|
An Expanded Role for IRBs in the Oversight of Research Biopsies.
|
|
Academic Article
|
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
|
|
Academic Article
|
Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?
|